Compare INTT & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTT | QNCX |
|---|---|---|
| Founded | 1981 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.2M | 17.5M |
| IPO Year | 1997 | 2019 |
| Metric | INTT | QNCX |
|---|---|---|
| Price | $10.77 | $29.48 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 2 |
| Target Price | ★ $13.50 | N/A |
| AVG Volume (30 Days) | ★ 97.6K | 14.1K |
| Earning Date | 05-05-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $66,801,000.00 | N/A |
| Revenue This Year | $15.82 | N/A |
| Revenue Next Year | $9.10 | N/A |
| P/E Ratio | $177.33 | ★ N/A |
| Revenue Growth | ★ 66.06 | N/A |
| 52 Week Low | $7.07 | $0.08 |
| 52 Week High | $20.00 | $35.41 |
| Indicator | INTT | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 35.57 | 48.26 |
| Support Level | $10.32 | $0.82 |
| Resistance Level | $10.88 | $35.38 |
| Average True Range (ATR) | 0.48 | 2.14 |
| MACD | 0.04 | -0.84 |
| Stochastic Oscillator | 7.28 | 34.79 |
inTest Corp is a supplier of test and process technology solutions for use in manufacturing and testing across a wide range of markets, including Semi, Auto/EV, Defense/Aerospace, Industrial, Life Sciences, Safety/Security, and Other. The Company has three operating segments, which are also its reportable segments and reporting units: Electronic Test, which generates the majority of its revenue and includes semiconductor test equipment, flying probe, and in-circuit testers; Environmental Technologies, which includes thermal test, process, and storage products; and Process Technologies, which includes induction heating and video imaging products. The Company generates the maximum revenue from the U.S.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.